Bright Minds Biosciences to Host Symposium on Therapeutic Developments within Dravet Syndrome and Featuring a Panel with Key Opinion Leaders
19 Abril 2022 - 5:50AM
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”)
(Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on
developing novel drugs for the targeted treatment of
neuropsychiatric disorders, epilepsy, and pain, today announced
that Ian McDonald, Chief Executive Officer, Dr. Revati Shreeniwas,
Chief Medical Officer, Professor John McCorvy, PhD, Senior Advisor,
and other key speakers will host a symposium on the recent
therapeutic developments within the Dravet Syndrome landscape. The
symposium will also include a panel with Key Opinion Leaders and a
Q&A session. In addition, the Company and KOLs will also
provide a developmental update on BMB-101, Bright Minds’ lead
R&D program for the treatment of Dravet Syndrome.
Date: |
Thursday, May
19, 2022 |
Time: |
10:00AM ET |
Webcast Live and Replay: |
https://brightmindsbio.com/investors/ |
An archived replay of the presentation will be
available on the Company’s website immediately following the
conference and will be available for 90 days at:
https://brightmindsbio.com/investors/.
Bright Minds further announces that in connection
with the entry into three consulting agreements related to
scientific services, the Company has issued an aggregate of 60,000
restricted share units of the Company (“RSUs”) pursuant to the
Company’s RSU plan, anticipates issuing an additional 25,000 common
shares in the capital of the Company (the “Common Shares”). The
RSUs are subject to vesting provisions pursuant to which 25% will
vest annually, commencing after one year of service, and all Common
Shares will be placed in a voluntary escrow, with 25% being
released annually, commencing on the one-year anniversary of
service. All securities issued are further subject to a hold period
of four months and one day from the date of issuance.
About BMB-101
BMB-101, a 5-HT2C selective and biased agonist, has
demonstrated compelling activity in a host of in-vitro and in-vivo
non-clinical tests. Compared to Locaserin, BMB-101 exhibits strong
Gq signaling coupled with minimal beta-arrestin recruitment.
Mechanistically, Serotonin (5- Hydroxytryptamine, 5-HT) is a
monoamine neurotransmitter widely expressed in the central nervous
system, and drugs modulating 5-HT have made a major impact in
mental health disorders. Central 5-HT systems have long been
associated with the control of ingestive behavior and the
modulation of behavioral effects of psychostimulants, opioids,
alcohol and nicotine. Over the past decade, the various 5-HT
receptor subtypes have been cloned and characterized. Results of
clinical trials and animal studies indicate that 5-HT2C up receptor
agonists may have therapeutic potential in the treatment of
addiction by decreasing the intake of opioids as well as impulsive
behavior that can escalate compulsive drug use.
About Dravet Syndrome
Dravet syndrome is an epilepsy syndrome that begins
in infancy or early childhood and can include a spectrum of
symptoms ranging from mild to severe. Children with Dravet syndrome
show focal (confined to one area) or generalized (throughout the
brain) convulsive seizures that start before 15 months of age
(often before age one). These initial seizures are often prolonged
and involve half of the body, with subsequent seizures that may
switch to the other side of the body. These initial seizures are
frequently associated with fever. Other seizure types emerge after
12 months of age and can be quite varied. Status epilepticus – a
state of continuous seizure requiring emergency medical care – may
occur frequently in these children, particularly in the first five
years of life. Dravet syndrome affects an estimated 1:15,700
individuals in the U.S., or 0.0064% of the population (Wu 2015).
Approximately 80-90% of those, or 1:20,900 individuals, have both
an SCN1A mutation and a clinical diagnosis of DS. This represents
an estimated 0.17% of all epilepsies. As an area of high, unmet
medical need, there currently exist only three FDA-approved
medications for the treatment of DS: (1) Fintepla® (fenfluramine),
which has a black-box label; (2) Diacomit® (stiripentol) and (3)
Epidolex® (cannabidiol).
About Bright Minds
Bright Minds is focused on developing novel
transformative treatments for neuropsychiatric disorders, epilepsy,
and pain. Bright Minds has a portfolio of next-generation serotonin
agonists designed to target neurocircuit abnormalities that are
responsible for difficult to treat disorders such as resistant
epilepsy, treatment resistant depression, PTSD, and pain. The
Company leverages its world-class scientific and drug development
expertise to bring forward the next generation of safe and
efficacious drugs. Bright Minds’ drugs have been designed to
potentially retain the powerful therapeutic aspects of psychedelic
and other serotonergic compounds, while minimizing the side
effects, thereby creating superior drugs to first-generation
compounds, such as psilocybin.
Investor Contacts: Lisa Wilson
In-Site Communications, Inc. 489 Fifth Avenue, 29th Floor New York,
NY 10017 E: lwilson@insitecony.com
Josh Blacher Bright Minds Biosciences, Inc. 19
Vestry Street New York, NY 10013 E: josh@brightmindsbio.com
Bright Minds Biosciences (NASDAQ:DRUG)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Bright Minds Biosciences (NASDAQ:DRUG)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024